These results indicated that GPC1-positive circulating exosomes used as a diagnostic tool are better than carbohydrate antigen 19-9 (CA 19-9), the main tumor biomarker used in the clinic for PDAC patients [41]. This evidence concerns the gene GPC1 and neoplasm.